Preclinical study demonstrates altered glucose kinetics in pancreatic ductal adenocarcinoma, indicating treatment effectiveness.
The study demonstrates that CP treatment fundamentally alters the metabolic kinetics of glucose in PDAC tumors, inducing disruptions in metabolic correlations that may serve for distinguishing therapeutic success from failure.
No takes yet. Share an insight, caveat, or question.
Montrazi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: